Older men whose testosterone levels drop or are medically suppressed face a measurably higher risk of age-related macular degeneration, the leading cause of irreversible blindness in developed countries. Multiple population-based studies, a Mendelian randomization analysis, and preclinical laboratory work now converge on the same signal: androgen levels and retinal health are linked in ways researchers are still working to explain. The findings carry real weight as testosterone prescriptions continue to climb among aging men seeking to offset fatigue, muscle loss, and low libido.
Why androgen levels and macular degeneration demand attention now
Age-related macular degeneration, or AMD, destroys central vision by damaging the macula, the small area of the retina responsible for sharp, detailed sight. A major clinical review in The New England Journal of Medicine established AMD as the top cause of irreversible vision loss among older adults in developed nations, affecting millions worldwide. Most treatment research has focused on anti-VEGF injections for wet AMD and antioxidant supplements for dry AMD. Far less work has examined whether hormonal shifts, specifically declining testosterone, independently raise AMD risk.
That gap matters because testosterone therapy use among older men has grown sharply over the past decade. If low testosterone promotes retinal degeneration, clinicians prescribing hormone replacement need to weigh eye health alongside cardiovascular and prostate considerations. And if testosterone suppression therapies used in prostate cancer treatment also increase AMD incidence, oncologists face a second, previously unrecognized trade-off when planning long-term care.
The hypothesis that genetic variants chronically lowering bioavailable testosterone could increase AMD incidence through impaired retinal pigment epithelium lipid clearance, rather than through VEGF upregulation, remains unproven but biologically plausible. The retinal pigment epithelium recycles photoreceptor outer segments in a lipid-intensive process, and androgen receptors are present in ocular tissue. If androgen signaling helps regulate that lipid metabolism, chronic deficiency could accelerate the drusen buildup characteristic of dry AMD. No study has yet isolated this pathway in human patients, but the direction of the evidence is consistent enough to warrant direct investigation.
Converging evidence from Taiwan, prostate cancer cohorts, and genetic analysis
A population-based cohort study published in Age and Ageing used Taiwan’s National Health Insurance Research Database with a 2010 to 2018 new-user, active-comparator design to examine men taking 5-alpha-reductase inhibitors for benign prostatic hyperplasia. These drugs suppress dihydrotestosterone, a potent androgen. The study found elevated AMD incidence among treated men compared with the active-comparator group, providing direct observational evidence that pharmacologic androgen suppression tracks with retinal disease.
A separate line of evidence comes from prostate cancer patients undergoing androgen deprivation therapy, or ADT. Research published in the Journal of Clinical Medicine examined whether ADT was associated with incident neovascular AMD and found that longer treatment duration correlated with greater risk after adjustment for confounders. Neovascular AMD is the more aggressive, wet form of the disease, which makes the association especially concerning for the roughly half-million American men on ADT at any given time.
Genetic evidence reinforces the direction of these observational findings. A Mendelian randomization analysis in Frontiers in Endocrinology used genetic instruments for steroid hormones, including testosterone and estradiol-related measures, to test potential causal effects on retinal neurodegenerative disease endpoints including AMD. Mendelian randomization reduces confounding by using genetic variants as proxies for lifelong hormone exposure, and the results supported a directional relationship between androgen levels and retinal disease risk, suggesting that testosterone is not merely an innocent bystander.
Mechanistic clues and conflicting signals from the lab
On the mechanistic side, laboratory experiments using a sodium iodate model of retinal degeneration found that testosterone can worsen photoreceptor injury in that specific context. The sodium iodate model does not perfectly replicate AMD, but it damages the retinal pigment epithelium and photoreceptors in ways that overlap with AMD pathology. The finding suggests androgen signaling can directly harm retinal cells under oxidative or toxic stress.
At first glance, that result seems to conflict with the population data linking low testosterone or pharmacologic suppression to higher AMD risk. One possible reconciliation is that androgen effects on the retina are dose- and context-dependent. In a stressed or acutely injured retina, higher testosterone might amplify damaging pathways such as oxidative stress, excitotoxicity, or inflammatory signaling. In the chronically aging eye, however, very low androgen tone could impair lipid handling, mitochondrial resilience, or microvascular support in the retinal pigment epithelium, predisposing to drusen accumulation and atrophy over decades.
Another possibility is that systemic metabolic changes induced by androgen deprivation-such as worsened insulin resistance, altered lipid profiles, or endothelial dysfunction-indirectly accelerate macular degeneration, while direct retinal androgen signaling remains protective in some compartments and harmful in others. Current data do not resolve these competing models, but they do argue strongly that testosterone is biologically active in the retina and choroid rather than neutral.
Signals from other macular diseases
Evidence from non-AMD macular disorders adds further weight to the notion that androgens shape ocular risk. A large database study in the American Journal of Ophthalmology reported that exogenous testosterone use increases the likelihood of central serous chorioretinopathy, a distinct but related macular condition characterized by subretinal fluid and visual distortion. Central serous chorioretinopathy has long been associated with corticosteroid exposure and stress, but the testosterone signal suggests that sex hormones more broadly modulate choroidal vascular permeability and retinal pigment epithelium barrier function.
While central serous chorioretinopathy and AMD differ in typical age of onset, clinical course, and histopathology, they share a dependence on healthy choroidal circulation and intact retinal pigment epithelium. The fact that both low androgen states (in ADT and 5-alpha-reductase inhibitor users) and high or supplemental androgen exposure (in testosterone users) associate with macular pathology strengthens the idea of a U-shaped risk curve: too little or too much androgen signaling may be detrimental, albeit through different mechanisms.
Clinical implications for prescribing and screening
For clinicians, the emerging evidence does not yet justify sweeping changes to testosterone prescribing, but it does support more deliberate risk–benefit conversations. Men starting or already on testosterone therapy, particularly those over 60 or with a family history of AMD, may benefit from baseline dilated eye exams and periodic macular imaging. Patients should be counseled to report new distortion, central blur, or difficulty reading promptly, as early detection of both AMD and central serous chorioretinopathy can meaningfully alter outcomes.
Oncologists managing prostate cancer with long-term androgen deprivation face a different calculus. For these patients, ADT is often life-prolonging, and discontinuation is rarely an option solely on ocular grounds. Still, awareness of elevated AMD and neovascular risk could encourage closer collaboration with ophthalmologists, earlier referral for visual symptoms, and consideration of modifiable co-factors such as smoking, hypertension, and poor diet that also drive macular degeneration.
Primary care physicians and endocrinologists should recognize that complaints of declining vision in men with known hypogonadism or on androgen-modulating drugs may warrant more urgent ophthalmic evaluation than in otherwise similar peers. Integrating eye health into comprehensive hormone management is a relatively low-cost step that could prevent avoidable visual disability.
What patients can do now
Men concerned about both testosterone and vision can take several practical steps while the science evolves. Smoking cessation, blood pressure control, and diets rich in leafy greens and omega-3 fatty acids remain the strongest evidence-based strategies for lowering AMD risk. Discussing any over-the-counter “testosterone boosters” or prescribed hormone regimens with both a medical doctor and, when appropriate, an eye specialist can help align endocrine and ocular care. Regular comprehensive eye exams, particularly after age 50, are critical for catching early macular changes regardless of hormone status.
Ultimately, the relationship between testosterone and retinal disease is unlikely to be simple. Yet the convergence of epidemiologic, genetic, and experimental data makes one conclusion clear: androgens matter for the aging eye. As testosterone use rises and more men live long enough to face AMD, integrating hormone biology into macular degeneration research and clinical practice is no longer optional-it is an overdue adjustment to how we think about vision in later life.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
